Navigation Links
FDA Warns About Weight Loss Products
Date:12/22/2008

Agency says more than 2 dozen contain dangerous ingredients not listed on label

MONDAY, Dec. 22 (HealthDay News) -- The U.S. Food and Drug Administration warned consumers Monday to avoid more than two dozen products marketed for weight loss because they contain undeclared ingredients that could pose serious health risks.

The products are sold in some retail stores and on the Internet and some claim to contain only "natural" or "herbal" ingredients. But the undeclared ingredients (not listed on labels) range from an anti-seizure medication to a suspected carcinogen, the FDA said.

The FDA identified the weight loss products as: Fatloss Slimming, Japan Lingzhi 24 Hours Diet, 7 Day Herbal Slim, 999 Fitness Essence, Imelda Perfect Slim, Perfect Slim, ProSlim Plus, Slim Express 360, Superslim, Venom Hyperdrive 3.0, 2 Day Diet, 5x Imelda Perfect Slimming, 8 Factor Diet, Extrim Plus, Lida DaiDaihua, Perfect Slim 5x, Royal Slimming Formula, Slimtech, TripleSlim, 3x Slimming Power, 3 Day Diet, 7 Diet Day/Night Formula, GMP, Miaozi Slim Capsules, Phyto Shape, Slim 3 in 1, Somotrim, and Zhen de Shou.

"These tainted weight loss products pose a great risk to public health because they contain undeclared ingredients and, in some cases, contain prescription drugs in amounts that greatly exceed their maximum recommended dosages," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a news release. "Consumers have no way of knowing that these products contain powerful drugs that could cause serious health consequences. Therefore, FDA is taking this action to protect the health of the American public."

The FDA said an analysis found that the undeclared ingredients in some of these products include sibutramine (a controlled substance), rimonabant (a drug not approved for marketing in the United States), phenytoin (an anti-seizure medication), and phenolphthalein (a solution used in chemical experiments and a suspected cancer-causing agent). Some of the amounts of active ingredients greatly exceed FDA-recommended levels, putting consumers' health at risk, the agency said.

The risks posed by these products can be serious, the FDA said. For instance, sibutramine, which was found in many of the products, can cause high blood pressure, seizures, palpitations, heart attack or stroke. The drug can also interact with other medications that patients may be taking and increase their risk of serious side effects. The safety of sibutramine also hasn't been determined for women who are pregnant or breast-feeding, or in children younger than 16 years of age, the agency said.

Rimonabant was evaluated -- but not approved -- by the FDA for marketing in the United States. The drug, which has been approved in Europe, has been associated with increased risk of depression and suicidal thoughts and has been linked to five deaths and 720 adverse reactions in Europe during the last two years, the agency said in the news release.

Consumers who have used any of these products should stop taking them immediately and consult their health-care professional. And consumers should always seek the guidance of a health-care professional before purchasing weight loss products, the FDA said.

The FDA said it has inspected a number of companies linked to the sale of these products, and is currently seeking to have the products recalled. Citing its own inspections and what it called the companies' "inadequate responses to recall requests," the agency said it may take additional action, including issuing warning letters or seeking criminal charges.

Health care professionals and consumers should report serious side effects or product quality problems to the FDA's MedWatch Adverse Event Reporting program. The e-mail address is www.fda.gov/MedWatch/report.htm. Or call (800) FDA-1088 or Fax (800) FDA-0178.

More information

To learn more, visit the FDA.



--HealthDay Staff



SOURCE: U.S. Food and Drug Administration, news release, Dec. 22, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose
2. Fast Heart Rate Warns of Obesity, Diabetes
3. New Poll Warns Daschle, Obama: Mandatory Health Insurance Big Loser With Public; Voters Want Return on Stem Cell Research
4. Another Study Warns of Risk From Cardiac Surgery Drug
5. Aged care workers to leave industry en masse due to stress, warns University of Melbourne study
6. Scientist Warns Industry Not to Ignore Potential Health Threat to Pharmacy Workers
7. Ceasefire Broken in Democratic Republic of Congo; International Medical Corps Warns of Looming Humanitarian Catastrophe and Wider Regional Impact
8. FDA Warns of Dangers of Mexican Vanilla
9. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
10. Humanitarian Needs From Georgia Conflict Still Growing, World Vision Warns
11. Lap-Band "Tell-All" Warns of Patients Becoming Lap-Band "Orphans"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... named Agency of Record (AOR) for Theravent, Inc. , the makers of ... parent company, Foundation Consumer Healthcare, is now working to expand distribution in anticipation ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... is seeking candidates to serve on its Accreditation and Standards Committees to ... ultimate mission is improving image quality and reducing patient radiation dose,” reports ...
(Date:4/21/2017)... ... ... and Overseer at The House of Yahweh in Abilene, Texas, wrote an open letter this ... to peace plan. Yisrayl says war has never brought peace and he knows the only ... , Yisrayl says war drums are beating all over the media and the tensions ...
(Date:4/21/2017)... ... April 21, 2017 , ... A ... for older shoulder replacement patients; post-operative recovery just might be even better than ... patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 patients ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology: